A5049398766- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- Hepatitis C virus research
- HIV/AIDS Research and Interventions
- Hepatitis B Virus Studies
- SARS-CoV-2 and COVID-19 Research
- Liver Disease Diagnosis and Treatment
- SARS-CoV-2 detection and testing
- Biochemical and Molecular Research
- Pneumocystis jirovecii pneumonia detection and treatment
- Vibrio bacteria research studies
- Viral Infections and Outbreaks Research
- vaccines and immunoinformatics approaches
- Systemic Lupus Erythematosus Research
- COVID-19 Clinical Research Studies
- Virology and Viral Diseases
- Plant Virus Research Studies
- Parvovirus B19 Infection Studies
- Biosensors and Analytical Detection
- Advanced biosensing and bioanalysis techniques
- Viral Infections and Immunology Research
- Animal Virus Infections Studies
- Viral gastroenteritis research and epidemiology
- Cytomegalovirus and herpesvirus research
- Toxoplasma gondii Research Studies
Istituti di Ricovero e Cura a Carattere Scientifico
2015-2024
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
2014-2024
Center for Prevention and Treatment of Infections
2020-2023
National Institute of Infectious Diseases
2021-2022
University of Palermo
2021
University of Rome Tor Vergata
2010-2020
Regione Puglia
2011
Policlinico Tor Vergata
2011
Indian Council of Agricultural Research
2010
University of Montenegro
2010
Background. We evaluated reliability and clinical usefulness of genotypic resistance testing (GRT) in patients for whom combination antiretroviral therapy (cART) was unsuccessful with viremia levels 50–1000 copies/mL, GRT is generally not recommended by current guidelines. Methods. The genotyping success rate 12 828 human immunodeficiency virus type 1 (HIV-1) plasma samples >50 tested using the commercial ViroSeq HIV-1 Genotyping System or a homemade system. Phylogenetic analysis performed...
Abstract The efficacy on the Omicron variant of approved early coronavirus disease‐2019 (COVID‐19) therapies, especially monoclonal antibodies, has been challenged by in vitro neutralization data, while data vivo antiviral activity are lacking. We assessed potential decrease from Day 1 to 7 viral load (VL) nasopharyngeal swabs outpatients receiving Sotrovimab, Molnupiravir, Remdesivir, or Nirmatrelvir/ritonavir for mild‐to‐moderate COVID‐19 due sublineages BA.1 BA.2, and average treatment...
Monoclonal antibody (mAb) therapy is one of the most promising immunotherapies that have shown potential to prevent or neutralize effects COVID-19 in patients at very early stages, with a few formulations recently approved by European and American medicine agencies. However, main bottleneck for their general implementation resides time-consuming, laborious, highly-specialized techniques employed manufacturing assessing these therapies, excessively increasing prices delaying administration...
With numbers of COVID-19 cases having substantially increased at the end 2022 in China, some countries have started or expanded testing and genomic surveillance travellers. We report screening results Italy late December 556 flight passengers provenance from two Chinese provinces. Among these passengers, 126 (22.7%) tested SARS-CoV-2 positive. Whole genome sequencing 61 passengers’ positive samples revealed Omicron variants, notably sub-lineages BA.5.2.48, BF.7.14 BQ.1.1, line with data...
Abstract Whole‐genome sequencing (WGS) has been widely used for the genomic characterization and phylogenesis of mpox virus (MPXV) 2022 multi‐country outbreak. To date, no evidence reported on intra‐host evolution within samples collected over time from a single patient with long‐term infection. Fifty‐one were five patients at different points post‐symptom onset. All confirmed as MPXV DNA positive, amplified by multiplexed PCR amplicon, sequenced WGS. Complete genomes assembled reference...
To define whether the prevalence of mutations associated with integrase inhibitor (INI) resistance is different in untreated versus antiretroviral-treated HIV-1-infected individuals (all INI naive).Gene sequences (IN) and reverse transcriptase (RT) obtained from plasma samples a well-defined cohort 448 (134 drug naive 314 antiretroviral treated) were analysed. Docking simulations, using RT IN models, also performed.Primary majority secondary for raltegravir or elvitegravir completely absent...
The dynamics of raltegravir-resistant variants and their impact on virologic response in 23 HIV-1-infected patients, who started a salvage raltegravir-containing regimen, were investigated.Integrase population sequencing Ultra-Deep-454 Pyrosequencing (UDPS) performed plasma samples at baseline raltegravir failure. All integrase mutations detected frequency ≥1% considered to be reliable for the UDPS analyses. Phylogenetic phenotypic resistance analyses also performed.At baseline, primary not...
Background Sub-Saharan Africa is endemic for intestinal parasites and distinguished the largest burden of HIV cases. Blastocystis sp. one most common protists infecting humans but its role in human disease still controversial. Aim this study was to investigate prevalence positive negative adults Ghana association with immune status other risk factors. Methods 122 outpatients 70 blood donors from Komfo Anokye Teaching Hospital Kumasi, Ghana, were included present study. Demographic, clinical...
Abstract Background We evaluated the prevalence of transmitted drug resistance (TDR) to integrase strand-transfer inhibitors (INSTIs) and nucleoside/nucleotide reverse transcriptase (NRTIs) clinically relevant (CRR) in newly diagnosed people with human immunodeficiency virus (HIV; PWH) naive antiretroviral therapy (ART) Europe. Methods MeditRes is a consortium that includes ART-naive PWH France, Greece, Italy, Portugal, Spain during 2018–2021. Reverse INSTI sequences were provided by...
We tested whether pre-HAART viraemia affects the achievement and maintenance of virological success in HIV-1-infected patients starting modern first-line therapies.A total 1,430 their first HAART (genotype-tailored) 2008 (median; IQR: 2006-2009) were grouped according to levels (≤ 30,000, 30,001-100,000, 100,001-300,000, 300,001-500,000 > 500,000 copies/ml). The impact pre-therapy on time (viraemia ≤ 50 copies/ml) rebound (first two consecutive values copies/ml after success) evaluated by...
Specific HBsAg mutations are known to hamper recognition by neutralizing antibodies thus challenging HBV-vaccination efficacy. Nevertheless, information on their impact and spreading over time is limited. Here, we characterize the circulation of vaccine-escape from 2005 2019 correlation with virological parameters in a large cohort patients infected HBV genotype-D (N = 947), dominant Europe. Overall, 17.7% harbours ≥1 mutation highest prevalence subgenotype-D3. Notably, complex profiles...
The goal of this study was to explore the presence integrase strand transfer inhibitor (InSTI) resistance mutations in HIV-1 quasispecies present InSTI-naïve patients and evaluate their vitro effects on phenotypic susceptibility InSTIs replication capacities. RT-RNase H-IN region PCR amplified from plasma viral RNA obtained 49 subtype B-infected (21 drug naïve 28 failing highly active antiretroviral therapy [HAART] not containing InSTIs) recombined with an HXB2-based backbone RT IN deleted....
Abstract Objectives Integrase drug resistance monitoring deserves attention because of the increasing number patients being treated with integrase strand-transfer inhibitors. Therefore, we evaluated genotyping success rate at low-level viraemia (LLV, 51–1000 copies/mL) and in raltegravir-failing patients. Methods An genotypic test (GRT) was performed on 1734 HIV-1 samples collected during 2006–13. Genotyping determined according to following levels: 51–500, 501–1000, 1001–10 000, 10 001–100...
Transition to dolutegravir-based regimens in resource-limited settings (RLS) requires prior understanding of HIV-1 integrase variants and conserved regions. Therefore, we evaluated drug resistance mutations (DRMs) regions amongst strand transfer inhibitor (INSTI)-naive patients harbouring diverse clades Cameroon.A cross-sectional study was conducted 918 INSTI-naive from Cameroon (89 ART-naive 829 ART-experienced patients). sequences were interpreted regarding INSTI-DRMs using the Stanford...
Abstract Objectives We evaluated the HIV-1 capsid genetic variability and lenacapavir drug resistance-associated mutations (DRMs) among drug-naive individuals across clades. Methods A total of 2031 sequences from patients were analysed for amino acid modification prevalence DRMs. Amino positions with <5% considered as conserved was by Results Overall, 63% (148/232) in protein. Of note, conservation consistent specific binding residues cellular factors involved viral replication [CypA...
Abstract Despite the higher transmissibility of Omicron Variant Concern (VOC), several reports have suggested lower risk for hospitalization and severe outcomes compared to previous variants SARS‐CoV‐2. This study, enrolling all COVID‐19 adults admitted a reference hospital who underwent both S‐gene‐target‐failure test VOC identification by Sanger sequencing, aimed describe evolving prevalence Delta compare main in‐hospital severity, during trimester (December 2021 March 2022) VOCs'...
We aimed to evaluate the prevalence and characteristics of people living with HIV (PLWH) eligible for long-acting injectable (LAI) regimen cabotegravir (CAB) rilpivirine (RPV), in comparison ineligible individuals.This was an observational, cross-sectional study from ARCA cohort, including virologically suppressed PLWH at least one genotypic resistance testing (GRT) reverse transcriptase integrase plasma and/or PBMCs. Eligibility criteria LAI CAB+RPV were: negative HBsAg, absence previous...
Limited data are available regarding the susceptibility of reverse transcriptase V106 polymorphism to doravirine.
Abstract Molnupiravir, an oral direct‐acting antiviral effective in vitro against SARS‐CoV‐2, has been largely employed during the COVID‐19 pandemic, since December 2021. After marketing and widespread usage, a progressive increase SARS‐CoV‐2 lineages characterized by higher transition/transversion ratio, characteristic signature of molnupiravir action, appeared Global Initiative on Sharing All Influenza Data (GISAID) International Nucleotide Sequence Database Collaboration (INSDC)...
Transmitted drug resistance (TDR) is still a critical aspect for the management of individuals living with HIV-1. Thus, its evaluation crucial to optimize HIV care.